PLX4032: does it keep its promise for metastatic melanoma treatment?

Author： Livingstone Elisabeth Zimmer Lisa Piel Sarah Schadendorf Dirk

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.19, Iss.11, 2010-11, pp. : 1439-1449

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Molecular Fundamentals and Rationale for Immunotherapy in Metastatic Melanoma Treatment

Clinical Cancer Drugs, Vol. 2, Iss. 1, 2015-05 ,pp. : 4-15

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular Fundamentals and Rationale for Immunotherapy in Metastatic Melanoma Treatment

Clinical Cancer Drugs, Vol. 2, Iss. 1, 2015-05 ,pp. : 4-15

Bentham Science Publishers

Access to resources Recommend Favorite

Alternating chemo-immunotherapy with temozolomide and interleukin-2 in the treatment of metastatic melanoma

Inpharma, Vol. 1, Iss. 1552, 2006-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma

By Patel Sapna P Kim Kevin B

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 4, 2012-04 ,pp. : 531-539

Informa Healthcare

Access to resources Recommend Favorite

Novel Immunotherapeutic Agents and Small Molecule Antagonists of Signalling Kinases for the Treatment of Metastatic Melanoma

By Natarajan Nagendra Telang Sucheta Miller Donald Chesney Jason

Drugs, Vol. 71, Iss. 10, 2011-07 ,pp. : 1233-1250

Adis International

Access to resources Recommend Favorite